{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:31:23Z","timestamp":1793266283177,"version":"4.5.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD052682"],"award-info":[{"award-number":["R01HD052682"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U01-NS116752-01A1"],"award-info":[{"award-number":["U01-NS116752-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Adeno-associated virus (AAV)-mediated gene therapy with delandistrogene moxeparvovec-rokl (Elevidys\u00ae) is an approved treatment for patients with Duchenne muscular dystrophy (DMD). While generally well tolerated, hepatotoxicity has been observed following its administration, leading to liver failure and death in two reported cases to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a case series describing four male patients with DMD, who received delandistrogene moxeparvovec-rokl at a single academic medical center and developed acute liver inflammation. All patients received corticosteroids, with doses increased as abnormalities developed, followed by the addtion of oral sirolimus (goal trough: 3\u20137\u2005ng\/ml), which was used primarily for T-cell immunomodulation. Monitoring included close clinical follow up, serial laboratory testing, and cardiac and functional assessments per institutional protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The patients were between 5 and 16 years of age with a weight between 20.8 and 56.7\u2005kg, (median: 32.5\u2005kg). Three boys were ambulatory. The four patients were receiving chronic corticosteroids for the treatment of DMD prior to delandistrogene moxeparvovec-rokl administration. All cases developed hepatic enzyme elevations five to seven weeks post-gene therapy. Treatment with high-dose corticosteroids led to transient improvement or worsening of laboratory abnormalities, and initiation of adjunctive sirolimus therapy resulted in normalization of gamma-glutamyl transferase and improvement of transaminases within two to four weeks. The duration of sirolimus treatment ranged from four to twelve weeks, during which corticosteroids were successfully weaned. None of the patients experienced hepatic synthetic dysfunction or serious infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These cases illustrate a subacute pattern of liver inflammation following AAV-gene therapy and support the potential role of mTOR inhibitors in managing AAV-related hepatotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/22143602261424971","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:17:02Z","timestamp":1773926222000},"page":"1263-1274","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-4301","authenticated-orcid":false,"given":"Carmen","family":"Leon-Astudillo","sequence":"first","affiliation":[{"name":"University of Florida"},{"name":"Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5530-8940","authenticated-orcid":false,"given":"Stephanie M","family":"Salabarria","sequence":"additional","affiliation":[{"name":"University of Florida"},{"name":"Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4981-9749","authenticated-orcid":false,"given":"Christina B","family":"Chadwick","sequence":"additional","affiliation":[{"name":"University of Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-2190","authenticated-orcid":false,"given":"Carla D","family":"Zingariello","sequence":"additional","affiliation":[{"name":"University of Florida"},{"name":"Department of Neurology, Montefiore Einstein Medical Center, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1058-3639","authenticated-orcid":false,"given":"Julie","family":"Berthy","sequence":"additional","affiliation":[{"name":"University of Florida"},{"name":"Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Prascak","sequence":"additional","affiliation":[{"name":"University of Florida"},{"name":"Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Shifflet","sequence":"additional","affiliation":[{"name":"University of Florida"},{"name":"Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Killian","sequence":"additional","affiliation":[{"name":"University of Florida"},{"name":"Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6391-4139","authenticated-orcid":false,"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[{"name":"University of Florida"},{"name":"Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5088-9774","authenticated-orcid":false,"given":"Lawrence","family":"Shoemaker","sequence":"additional","affiliation":[{"name":"University of Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-1756","authenticated-orcid":false,"given":"Barry J","family":"Byrne","sequence":"additional","affiliation":[{"name":"University of Florida"},{"name":"Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.045"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173510"},{"key":"e_1_3_3_5_2","unstructured":"Food and Drug Administration. FDA Investigating Deaths Due to Acute Liver Failure in Non-ambulatory Duchenne Muscular Dystrophy Patients Following ELEVIDYS 2025. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-deaths-due-acute-liver-failure-non-ambulatory-duchenne-muscular-dystrophy-patients."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.12.010"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00313-7"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.11.007"},{"key":"e_1_3_3_9_2","unstructured":"Food and Drug Administration. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy 2023. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy."},{"key":"e_1_3_3_10_2","unstructured":"Food and Drug Administration. FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy 2024 [Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy."},{"key":"e_1_3_3_11_2","unstructured":"Sarepta Therapeutics. Sarepta announces FDA's approval of updated ELEVIDYS prescribing information 2025 [Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-announces-fdas-approval-updated-elevidys-prescribing."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26755"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03304-z"},{"key":"e_1_3_3_14_2","unstructured":"Food and Drug Administration. ELEVIDYS. Highlights of prescribing information https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-ELEVIDYS_1.pdf2025 [Available from: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-ELEVIDYS_1.pdf."},{"key":"e_1_3_3_15_2","unstructured":"Sarepta Therapeutics. Community Letter: ELEVIDYS Safety Update https:\/\/www.sarepta.com\/community-letter-elevidys-safety-update#:\u223c:text=Breadcrumb the%20information%20from%20this%20event.2025 [Available from: https:\/\/www.sarepta.com\/community-letter-elevidys-safety-update#:\u223c:text=Breadcrumb the%20information%20from%20this%20event."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101296"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2022.05.001"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.02.002"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/2058738420934936"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000245377.93401.39"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00324.x"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129658"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/10430342251385586"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.33"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172614"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.017"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001530"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v17.i9.110264"},{"key":"e_1_3_3_30_2","unstructured":"Sarepta Therapeutics. An Elevidys safety update in non ambulatory patients 2025. Available from: https:\/\/investorrelations.sarepta.com\/static-files\/8ea1d085-617e-4586-a837-8bd6c5f22f33."},{"key":"e_1_3_3_31_2","unstructured":"Wolff J Capocci N Atas E et al. Consensus recomendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy Journal of Neuromuscular disorders. 2025:in press."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.03.002"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-306647"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/01926233231201408"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16065"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210712"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314518"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12163"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.06.001"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.01.016"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03243-5"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm420"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.06.003"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200109150-00008"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200005270-00019"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1132698"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199904150-00017"},{"key":"e_1_3_3_48_2","first-page":"967","article-title":"Severe sirolimus-induced acute hepatitis in a renal transplant recipient","volume":"23","author":"Jacques J","year":"2010","unstructured":"Jacques J, Dickson Z, Carrier P, et al. Severe sirolimus-induced acute hepatitis in a renal transplant recipient. Transpl Int 2010; 23: 967\u2013970.","journal-title":"Transpl Int"},{"key":"e_1_3_3_49_2","unstructured":"Administration FaD. Rapamune (sirolimus) label. 2017."},{"key":"e_1_3_3_50_2","unstructured":"Sarepta. Community Letter: Elevidys Safety update 2025 [Available from: https:\/\/www.sarepta.com\/community-letter-elevidys-safety-update#:\u223c:text=Breadcrumb the%20information%20from%20this%20event."}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602261424971","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/22143602261424971","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602261424971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:31:43Z","timestamp":1793262703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/22143602261424971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/22143602261424971"],"URL":"https:\/\/doi.org\/10.1177\/22143602261424971","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]}}}